Dermatology

Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of ustekinumab as a new treatment option for patients aged 6 years or older with active psoriatic arthritis.

Arcutis Biotherapeutics’ roflumilast cream will provide relief to patients aged 12 years or older diagnosed with plaque psoriasis.

A healthy 14-year old boy was evaluated for an intensely pruritic shin rash that developed 2 weeks prior and had been treated with oral antibiotics for 10 days.

Stephen Stripling, MD, FAAP, discusses results published in JAMA Dermatology about the efficacy and safety of berdazimer gel 10.3% for the treatment of molluscum contagiosum.

Opzelura (ruxolitinib) cream is the first and only FDA-approved treatment for adult and pediatric patients 12 years of age or older with vitiligo.

A better understanding of this atopic diathesis and the atopic march often seen in pediatric patients is necessary to optimally treat and manage the patient population, ideally in a multidisciplinary setting.

Investigators suggest parents and clinicians should be mindful of children with suspected ACD with a history of exposure to jewelry, clothing, and belts with cobalt.

At an SPD 2022 47th Annual Meeting poster session, researchers look at gender and age differences in pediatric patients with melanoma.

At the SPD 2022 47th Annual Meeting, a poster session looks at the updated guidelines for rosacea, and whether they are inclusive of children.

At the SPD 2022 47th Annual Meeting, we chat with Albert Yan, MD, of Children's Hospital of Philadelphia on the latest trends in technology for pediatric dermatologists.

At the SPD 2022 47th Annual Meeting, a recap of don’t-miss sessions for Sunday, July 10.

At the SPD 2022 47th Annual Meeting, a very funny—and informative—discussion on the pros and cons of telehealth in dermatology.

At the SPD 2022 47th Annual Meeting in Indianapolis, a pediatric dermatologist shares his views on what we have learned From the COVID-19 pandemic.

At the SPD 2022 47th annual meeting, investigators share data on the treatment of ruxolitinib for this chronic autoimmune disease.

At the SPD 2022 47th Annual Meeting, a discussion of the latest therapeutics for acne.

At the SPD 2022 47th Annual Meeting in Indianapolis, Candrice R. Heath, MD, FAAP, FAAD share compelling best practices for treating patients of color with this condition.

At the SPD 2022 47th Annual Meeting, a discussion of habitual orders in children and adolescents, such as skin picking.

Bernard A. Cohen, MD, shares what he thinks will be most exciting at this year's Society for Dermatology Meeting in Indianapolis, Indiana.

Cynthia J. Trickett, PA-C, MPAS, discusses the personal and clinical effects of atopic dermatitis in adult and pediatric patients at the 2022 Maui Dermatology Conference for PAs & NPs.

At the SPD 2022 47th Annual Meeting in Indianapolis, Indiana, a poster session on atopic dermatitis severity and outcomes in young children from 5 regions around the world.

Verrica is complying with the FDA through 3 Complete Response Letters to achieve the first FDA-approved treatment of molluscum contagiosum.

The approvals were based on results from the JUNIPERA trial, which showed secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA.

From pediatric dermatology quizzes to the latest news in telederm to practical pearls on atopic dermatitis, alopecia, and vitiligo, there’s a lot going on at the SPD 2022 47th Annual Meeting, this year in Indianapolis, Indiana.

You will find dermatologic studies from the rare (annual erythema of infancy) to the common (atopic dermatitis) and lots in between at the poster sessions at this year's SPD 2022 47th Annual Meeting in Indianapolis, Indiana.

A wide array of fascinating sessions are being presented this year at the SPD 2022 47th Annual Meeting in Indianapolis, Indiana.